Researching Effective Strategies to Prevent Opioid Death (RESPOND)
研究预防阿片类药物死亡的有效策略(RESPOND)
基本信息
- 批准号:10804924
- 负责人:
- 金额:$ 89.58万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2018
- 资助国家:美国
- 起止时间:2018-06-01 至 2028-07-31
- 项目状态:未结题
- 来源:
- 关键词:Accident and Emergency departmentAddressAffectAmbulatory CareBlack PopulationsBuprenorphineCalibrationCaringClinicalColorCommunitiesConsolidated Framework for Implementation ResearchCost Effectiveness AnalysisCost MeasuresCosts and BenefitsDataDrug PrescriptionsDrug usageDrug userEconomicsEnsureEpidemiologyEquityFundingGenderGrantHealthHealth BenefitImprisonmentInterventionInvestmentsJusticeKentuckyLatinx populationMental HealthMethodsModelingNational Institute of Drug AbuseNeedle-Exchange ProgramsNew YorkOhioOpioidOutcomeOverdosePersonsPharmaceutical PreparationsPoliciesPopulationPrescription opioid overdosePublic HealthPublishingRaceRacial EquityService delivery modelSpecial PopulationStructural RacismWomancollaborative carecostcost effectivenesscost estimatedata infrastructureeconomic impacteconomic valuegender disparityhealth economicshealth equityimplementation frameworkimplementation studyimprovedinnovationinterestmedication for opioid use disordermenmethadone treatmentmodels and simulationnovelopioid epidemicopioid mortalityopioid overdoseopioid use disorderoverdose deathpeople of colorpreventracial disparityresponsetelehealthtool
项目摘要
PROJECT SUMMARY
Between April 2021 and March 2022, the U.S. endured over 100,000 drug overdose deaths. As the opioid
epidemic expands, the epidemiology of overdose is changing. Nationally, the rate of overdose in Black and
Latinx people is growing more than five times faster than it is among white people. Similarly, between 1999-
2015, the prescription opioid overdose rate among women increased at more than twice the rate for men.
While differences in opioid supply could explain some racial and gender disparities, the ways that we
implement opioid treatment could also drive them. It is therefore essential that we investigate how
implementation of policy and interventions to address the opioid crisis impacts health equity.
The Researching Effective Strategies to Prevent Opioid Death (RESPOND) is simulation model OUD and OUD
treatment delivery in a state. RESPOND leverages investments in expanded public health data infrastructure to
inform model parameters, and it catalyzes new uses of data from NIDA-funded implementation studies. We
use RESPOND to investigate the health benefits, costs, and cost-effectiveness of policy choices and health
care delivery models to prevent opioid overdose. In the previous funding period, we developed RESPOND and
published studies projecting public health and health economic impacts of expanding the availability of
medications for opioid use disorder (MOUD) in a variety of settings. We are currently expanding RESPOND to
simulate outcomes in Kentucky, Ohio, and New York.
We now propose to enhance RESPOND to investigate outcomes among populations of special interest to
opioid response: 1) communities of color and 2) women. We will then use the model to investigate health
economic and health equity impacts of policies regulating prescribing for medications for OUD and innovative
care delivery models for people with OUD. We will perform distributional cost-effectiveness analyses, which is
an emerging and innovative method to investigate trade-offs between maximizing population-level benefits and
ensuring equitable distribution of costs and benefits. Our specific aims are:
Aim 1: To enhance the RESPOND model and calibrate it to race and gender stratified targets in order to
focus on populations of interest in the opioid crisis: people of color and women
Aim 2: To use RESPOND to perform distributional cost-effectiveness analyses of changing policies
regulating MOUD prescribing
Aim 3: To employ RESPOND to investigate the clinical, racial equity impact, and economic value of
interventions that support people who use drugs along each step of the OUD care cascade.
We use RESPOND to generate evidence to guide large-scale implementation of policies and interventions to
prevent overdose. In the coming 5-years we will continue to be leaders in the field of OUD simulation modeling
and will employ RESPOND as an important tool for justice in the opioid crisis.
项目摘要
在2021年4月至2022年3月期间,美国经历了超过10万例药物过量死亡。作为阿片类药物
流行病扩大,过量的流行病学正在发生变化。在全国范围内,黑人和
拉丁裔人口的增长速度是白色人的五倍多。同样,在1999-
2015年,女性的处方阿片类药物过量率增加了男性的两倍多。
虽然阿片类药物供应的差异可以解释一些种族和性别差异,但我们的方式,
实施阿片类药物治疗也可能驱使他们。因此,我们必须研究如何
为解决类阿片危机而实施的政策和干预措施影响到卫生公平。
研究预防阿片类药物死亡的有效策略(RESPOND)是仿真模型OUD和OUD
在一个国家进行治疗。RESPOND利用对扩大的公共卫生数据基础设施的投资,
为模型参数提供了信息,并促进了对来自NIDA资助的实施研究的数据的新用途。我们
使用RESPOND调查政策选择和健康的健康效益、成本和成本效益
护理模式,以防止阿片类药物过量。在上一个资助期,我们开发了RESPOND,
已发表的研究报告预测了扩大卫生保健服务供应对公共卫生和卫生经济的影响,
阿片类药物使用障碍(MOUD)在各种设置。我们目前正在扩大RESPOND,
模拟肯塔基州、俄亥俄州和纽约结果。
我们现在建议加强RESPOND,以调查特别感兴趣的人群的结果,
阿片类药物反应:1)有色人种社区和2)女性。然后,我们将使用该模型来研究健康
规范OUD和创新药物处方的政策对经济和健康公平性的影响
为OUD患者提供护理模式。我们将进行分销成本效益分析,
这是一种新兴的创新方法,用于调查最大限度地提高人口效益和
确保公平分配成本和收益。我们的具体目标是:
目标1:加强RESPOND模型,并根据种族和性别分层目标对其进行校准,
关注阿片类药物危机中的利益人群:有色人种和妇女
目标2:使用RESPOND对不断变化的政策进行分配成本效益分析
规范MOUD处方
目的3:使用RESPOND调查临床、种族公平影响和经济价值,
在OUD护理级联的每个步骤中支持吸毒者的干预措施。
我们使用RESPOND来生成证据,以指导政策和干预措施的大规模实施,
防止过量服用。在未来的5年里,我们将继续成为OUD仿真建模领域的领导者
并将使用RESPOND作为阿片类药物危机中正义的重要工具。
项目成果
期刊论文数量(3)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
Infective Endocarditis in Persons Who Use Drugs: Epidemiology, Current Management, and Emerging Treatments.
- DOI:10.1016/j.idc.2020.06.004
- 发表时间:2020-09
- 期刊:
- 影响因子:4.4
- 作者:Schranz A;Barocas JA
- 通讯作者:Barocas JA
Association of Treatment With Medications for Opioid Use Disorder With Mortality After Hospitalization for Injection Drug Use-Associated Infective Endocarditis.
- DOI:10.1001/jamanetworkopen.2020.16228
- 发表时间:2020-10-01
- 期刊:
- 影响因子:13.8
- 作者:Kimmel SD;Walley AY;Li Y;Linas BP;Lodi S;Bernson D;Weiss RD;Samet JH;Larochelle MR
- 通讯作者:Larochelle MR
Opioid use disorder and overdose among youth following an initial opioid prescription.
- DOI:10.1111/add.15487
- 发表时间:2021-10
- 期刊:
- 影响因子:0
- 作者:Hadland SE;Bagley SM;Gai MJ;Earlywine JJ;Schoenberger SF;Morgan JR;Barocas JA
- 通讯作者:Barocas JA
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Benjamin P. Linas其他文献
153: THE HEPATITIS C CARE CASCADE DURING THE DIRECT-ACTING ANTIVIRAL ERA WITHIN A NATIONALLY REPRESENTATIVE UNITED STATES HEALTH CLAIMS DATABASE
- DOI:
10.1016/s0016-5085(22)62685-4 - 发表时间:
2022-05-01 - 期刊:
- 影响因子:
- 作者:
Nicole Ferrante;Craig Newcomb;Charles Leonard;Jessie Torgersen;Sarah Rowan;Benjamin P. Linas;David L. Wyles;Jay Kostman;Kimberly A. Forde;Stacey Trooskin;Vincent Lo Re - 通讯作者:
Vincent Lo Re
Publisher Correction: Long COVID impacts: the voices and views of diverse Black and Latinx residents in Massachusetts
- DOI:
10.1186/s12889-024-19890-z - 发表时间:
2024-09-12 - 期刊:
- 影响因子:3.600
- 作者:
Linda Sprague Martinez;Nihaarika Sharma;Janice John;Tracy A. Battaglia;Benjamin P. Linas;Cheryl R. Clark;Linda B. Hudson;Rebecca Lobb;Gillian Betz;Shayne Orion Ojala O’Neill;Angelo Lima;Ross Doty;Syeeda Rahman;Ingrid V. Bassett - 通讯作者:
Ingrid V. Bassett
Primary Care Physicians’ Preparedness to Recognize and Evaluate Patients for Long COVID
- DOI:
10.1007/s11606-025-09387-9 - 发表时间:
2025-01-22 - 期刊:
- 影响因子:4.200
- 作者:
Nicole D. Kaufmann;Kathleen M. Mazor;Jai Marathe;Benjamin P. Linas;Kimberly A. Fisher - 通讯作者:
Kimberly A. Fisher
Abatacept Pharmacokinetics and Exposure Response in Patients Hospitalized With COVID-19
COVID-19 住院患者的阿巴西普药代动力学和暴露反应
- DOI:
- 发表时间:
2024 - 期刊:
- 影响因子:13.8
- 作者:
Stephen J. Balevic;Daniel K. Benjamin;W. G. Powderly;P. B. Smith;Daniel Gonzalez;Matthew W McCarthy;Linda K Shaw;C. J. Lindsell;Sam Bozzette;Daphne Williams;Benjamin P. Linas;J. Blamoun;H. Javeri;Christoph P. Hornik;Mahendra Patel;Arun J Sanyal;Jason Green;Huimin Wu;Benjamin P. Linas;Philip Grant;Vivek Iyer;Otto Yang;Bindu Balani;Sam Parnia;Ryan Dare;Caryn Morse;Estelle S. Harris;Glenn Wortmann;Nicholas Hill;Shama Patel;Julia Garcia;Suman Thapamager;Megan Devine;Christine M. Bojanowski;Barry Meisenberg;Gailen Marshall;D. Dandachi;Arick Sabin;Anthony Breemo;Suman Sinha;Christopher Goss;Rebecca Reece;Arlette Aouad;Seth Glassman;Peter Morris;Bela Patel;Fatimah Bello;Juliana Cardozo Fernandes;Oscar Carbajal;L. Ravera;Mozar Castro;Miguel Villegas;Fernando Oscar Riera;Adrian Camacho;Claudio Stadnik;Jorge Gave;Rodrigo Biondi;Ronal Gamarra Velarde;José Cerbino Neto;J. Ditondo;Marcelo H. Losso;Mariano Dolz;Alexandra O’Sullivan;Brian Gavin;M. Beumont‐Mauviel;Huyen Ca;R. Beci;Daniel Molina;Sandhya Rao;Thomas Stock;William Erhardt;Sarah Read;Jessica Springer;Rachel Presti;Ryley Thompson;Kimberly Gray;Cathy Henry;Alem Haile;Michael Klebert;L. Kessels;Kathryn Vehe;Kristopher Bakos;Teresa Spitz;Sara Hubert;Raghd Alyatim;Brittany Schneider;Chapelle A Ayres;A. Spec;L. Blair;Anita Afghanzada;Natalie Schodl;L. Wahid;John J. Engemann;Gloria Pinero;Beth McLendon;Lynn Whitt;Jenny Shroba;Elizabeth Salsgiver;Candace Alleyne;Anna Gwak;Nicholas Pickell;Jack Spagnoletti;Samson Goh;Katharine Robb;Michael Cenname;Catherine Small;Markus Plate;Rodrigo Burgos;Brenna Lindsey;Fischer Herald;Stephanie Echeverria;Dorendra Lewis;Mahesh Patel;Charles D. Bengtson;Andreas Schmid;Kimberly Lovell;C. Lovelett;Daniel Soule;Daniel Jaremczuk;Jennie Flanagan;Cameron Murray;Kylie Sands;Kyle Flint;Sara Mohaddes;Caryn Harrington;Kylie Broughal;David Sogoian;Karen Cox;H. Javeri;Philip O. Ponce;D. O. Dixon;Jason E. Bowling;Jan E. Patterson;Barbara S. Taylor;Ruth C. Serrano;Kaylin Sallee;Robin E Tragus;Gabriel Catano;Irma Scholler;Rose Ann Barajas;Armando Garcia;Bridgette T. Soileau;Patricia Heard;Manuel Camilo Endo Carvajal;Rukevwe Ehwarieme;Divya Chandramohan;Alejandro Cabo;Abdelhameed Nawwar;C. Quill;Nayeem Choudhury;Ashley Arrington;Isaiah Holyfield;Abby Smith;Glenda Brown;Kyle Varner;Joni Baxter;Tracy Roundy;Mary Co;Mireya Wessolossky;Juan Perez;Jennifer Holter;Brittany Karfonta;Juvaria Anjum;Jai Marathe;Myriam Castagne;D. Mompoint;Ryan Schroeder;Mallika Rao;Johnathan Nguyen;J. Plewa;Sue Donlinger;Marylynn Breslin;S. Dodson;Mitch Jenkins;John Williamson;E. Middleton;Mai Tavadze;Romai Sebhatu;Jessica Pierobon;Nate Miller;John Lee;Pratik Doshi;Andrew Dentino;Jessica Martin;Erik Hinojosa;Pablo Torres;Ricardo Sanchez;Gladys Murga;Silvana de la Gala;Jhon Chaiña;Jorge Ramos;Jenny Malca;Kathia Castillo;Johana Calderon Galvez;Maria Lyda Icochea Perez;Claudia Carolina Becerra Nunez;Sandra Betteta Riondato;Sandra Delgado Málaga;Cecilia Barreda Sánchez;Sylvia Sánchez Morales;Myriam Yaringano Palacios;Dora Galarza Cuba;Ivan Hermenegildo;Mayra Falla Benites;Stefania Neyra;Josefina Hernández;Victoria García;Katherine Palacios;Miluska Matos;Fiorella Zuloeta;Fiorella del Carpio;Gloria Chacaltana;Carmen de la Cruz;Felipe Ceriolli Breda;Mauricio Mello Roux Leite;T. Milbradt;Luz Rodeles;Nadia Benzaquen;Sebastian Pezzini;Lucila Alberdi;P. Serravalle;Giulia Russo;F. Ferini;M. Guala;Alejandro Crespo;Agostina Benitez;Maria Elena Cristaldi;Paula Di Renzo;Corina Gramagalia;Antonela Tessini;Joana Evelin Alonso;Carmen Pic;Georgina Ceraldi;Azucena Mondino;Iliana Higareda Almaraz;Víctor Hugo Madrigal Robles;María Fernanda Rosas Ismerio;Maria Fernanda Rodarte Rodriguez;Norma Esther Olmos Meza;Norma Esther de la Cruz Barba;Ana Maria Alba Ponce;Juan Manuel Calderon;Eduardo Borsetta;Noemí Sandoval;Daniela Vazquez;Malena Mansilla;Marta Molina;Yamila Jara;Laura De Bona;Maria Eduarda Claus;Arthur Pille;M. Lahitte;Mariángeles Fenés;Cecilia Bianchi;María Emilia Miserere;M. F. Alzogaray;Halbert Christian Sanchez Carrillo;Aldana Mano;Myrna Zuain;J. Toibaro;Valeria Pachioli;Sebastián Chaio;Natalia Malamud;D. Bharucha;Patrick B. Dorr;Jonathan Sadeh;Sheila Kelly;Marita Stevens;Huyen Cao;Adam DeZure;K. Juneja;Mazin Abdelghany;Theresa Jasion;Rachel E. Olson;Megan Roebuck;J. Huvane;C. J. Lindsell;Jeff Leimberger;Eric Yow;Zhen Huang;Hwasoon Kim;Carla Anderson;Carrie Elliott;Merri Swartz;Jyotsna Garg;Neta Nelson;Divya Kalaria;Ketty Philogene;Tim Schulz;Averie Kuek;Fatou Bah;Jarrard Mitchell;Elizabeth Polo;Michelle Wong;Sharon Baldan;Sandra Mendez;Bradford Stevens;Marcela Toledo;Talita Abba;Emma Herrejon;Cristina Gomez;Georgeta Mardari;Neeraja Putta;Robin Mason;Holli Hamilton;Derek Eisnor;Anna O’Rourke;Aditi Patel;Betty Brody;Anna Chiang;Brian Lind;Lilli M. Portilla;Ami D. Gadhia;Sury Vepa;Emily Carlson Marti;Bobbi Gardner;J. Rutter;Clare Schmitt;Michael Kurilla - 通讯作者:
Michael Kurilla
T84 - Health and Economic Outcomes of Offering Buprenorphine in Shelters in Massachusetts: Results of a Simulation Model
T84 - 马萨诸塞州庇护所提供丁丙诺啡的健康和经济结果:模拟模型的结果
- DOI:
10.1016/j.drugalcdep.2024.111852 - 发表时间:
2025-02-01 - 期刊:
- 影响因子:3.600
- 作者:
Emily Stewart;Avik Chatterjee;Sabrina A. Assoumou;Stavroula A. Chrysanthopoulou;Rebecca Arden Harris;Ryan O'Dea;Bruce Schackman;Laura White;Benjamin P. Linas - 通讯作者:
Benjamin P. Linas
Benjamin P. Linas的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Benjamin P. Linas', 18)}}的其他基金
HEAL Data2Action Modeling and Economic Resource Center
HEAL Data2Action 建模和经济资源中心
- 批准号:
10590443 - 财政年份:2022
- 资助金额:
$ 89.58万 - 项目类别:
HEAL Data2Action Modeling and Economic Resource Center
HEAL Data2Action 建模和经济资源中心
- 批准号:
10708099 - 财政年份:2022
- 资助金额:
$ 89.58万 - 项目类别:
Researching Effective Strategies to Prevent Opioid Death (RESPOND)
研究预防阿片类药物死亡的有效策略(RESPOND)
- 批准号:
10369647 - 财政年份:2018
- 资助金额:
$ 89.58万 - 项目类别:
Researching Effective Strategies to Prevent Opioid Death (RESPOND)
研究预防阿片类药物死亡的有效策略(RESPOND)
- 批准号:
9891990 - 财政年份:2018
- 资助金额:
$ 89.58万 - 项目类别:
Simulation Modeling to Improve HIV/HCV Screening, Treatment and Care
模拟建模改善 HIV/HCV 筛查、治疗和护理
- 批准号:
8846562 - 财政年份:2012
- 资助金额:
$ 89.58万 - 项目类别:
Simulation Modeling to Improve HIV/HCV Screening, Treatment and Care
模拟建模改善 HIV/HCV 筛查、治疗和护理
- 批准号:
8263169 - 财政年份:2012
- 资助金额:
$ 89.58万 - 项目类别:
Simulation Modeling to Improve HIV/HCV Screening, Treatment and Care
模拟建模改善 HIV/HCV 筛查、治疗和护理
- 批准号:
8662217 - 财政年份:2012
- 资助金额:
$ 89.58万 - 项目类别:
Simulation Modeling to Improve HIV/HCV Screening, Treatment and Care
模拟建模改善 HIV/HCV 筛查、治疗和护理
- 批准号:
8862651 - 财政年份:2012
- 资助金额:
$ 89.58万 - 项目类别:
Simulation Modeling to Improve HIV/HCV Screening, Treatment and Care
模拟建模改善 HIV/HCV 筛查、治疗和护理
- 批准号:
8486407 - 财政年份:2012
- 资助金额:
$ 89.58万 - 项目类别:
Improving HIV and HCV outcomes in U.S. AIDS Drug Assistance Programs
改善美国艾滋病药物援助计划中的艾滋病毒和丙型肝炎治疗结果
- 批准号:
7339148 - 财政年份:2007
- 资助金额:
$ 89.58万 - 项目类别:
相似海外基金
Rational design of rapidly translatable, highly antigenic and novel recombinant immunogens to address deficiencies of current snakebite treatments
合理设计可快速翻译、高抗原性和新型重组免疫原,以解决当前蛇咬伤治疗的缺陷
- 批准号:
MR/S03398X/2 - 财政年份:2024
- 资助金额:
$ 89.58万 - 项目类别:
Fellowship
CAREER: FEAST (Food Ecosystems And circularity for Sustainable Transformation) framework to address Hidden Hunger
职业:FEAST(食品生态系统和可持续转型循环)框架解决隐性饥饿
- 批准号:
2338423 - 财政年份:2024
- 资助金额:
$ 89.58万 - 项目类别:
Continuing Grant
Re-thinking drug nanocrystals as highly loaded vectors to address key unmet therapeutic challenges
重新思考药物纳米晶体作为高负载载体以解决关键的未满足的治疗挑战
- 批准号:
EP/Y001486/1 - 财政年份:2024
- 资助金额:
$ 89.58万 - 项目类别:
Research Grant
Metrology to address ion suppression in multimodal mass spectrometry imaging with application in oncology
计量学解决多模态质谱成像中的离子抑制问题及其在肿瘤学中的应用
- 批准号:
MR/X03657X/1 - 财政年份:2024
- 资助金额:
$ 89.58万 - 项目类别:
Fellowship
CRII: SHF: A Novel Address Translation Architecture for Virtualized Clouds
CRII:SHF:一种用于虚拟化云的新型地址转换架构
- 批准号:
2348066 - 财政年份:2024
- 资助金额:
$ 89.58万 - 项目类别:
Standard Grant
The Abundance Project: Enhancing Cultural & Green Inclusion in Social Prescribing in Southwest London to Address Ethnic Inequalities in Mental Health
丰富项目:增强文化
- 批准号:
AH/Z505481/1 - 财政年份:2024
- 资助金额:
$ 89.58万 - 项目类别:
Research Grant
ERAMET - Ecosystem for rapid adoption of modelling and simulation METhods to address regulatory needs in the development of orphan and paediatric medicines
ERAMET - 快速采用建模和模拟方法的生态系统,以满足孤儿药和儿科药物开发中的监管需求
- 批准号:
10107647 - 财政年份:2024
- 资助金额:
$ 89.58万 - 项目类别:
EU-Funded
BIORETS: Convergence Research Experiences for Teachers in Synthetic and Systems Biology to Address Challenges in Food, Health, Energy, and Environment
BIORETS:合成和系统生物学教师的融合研究经验,以应对食品、健康、能源和环境方面的挑战
- 批准号:
2341402 - 财政年份:2024
- 资助金额:
$ 89.58万 - 项目类别:
Standard Grant
Ecosystem for rapid adoption of modelling and simulation METhods to address regulatory needs in the development of orphan and paediatric medicines
快速采用建模和模拟方法的生态系统,以满足孤儿药和儿科药物开发中的监管需求
- 批准号:
10106221 - 财政年份:2024
- 资助金额:
$ 89.58万 - 项目类别:
EU-Funded
Recite: Building Research by Communities to Address Inequities through Expression
背诵:社区开展研究,通过表达解决不平等问题
- 批准号:
AH/Z505341/1 - 财政年份:2024
- 资助金额:
$ 89.58万 - 项目类别:
Research Grant